Antisense oligonucleotides (ASOs) are used to selectively inhibit the translation of disease-
associated genes via Ribonuclease H (RNaseH)-mediated cleavage or steric hindrance …

The first published description of therapeutic applications of antisense oligonucleotide
(ASO) technology occurred in the late 1970s and was followed by the founding of …

Antisense oligonucleotides (ASOs) bind sequence specifically to the target RNA and
modulate protein expression through several different mechanisms. The ASO field is an …

Antisense oligonucleotides (ASOs) represent a new and highly promising class of drugs for
personalized medicine. In the last decade, major chemical developments and improvements …

Antisense therapy has been investigated extensively over the past two decades, either
experimentally for gene functional research or clinically as therapeutic agents owing to the …

Antisense oligonucleotides (ASOs) are an increasingly represented class of drugs. These
small sequences of nucleotides are designed to precisely target other oligonucleotides …

Targeting unique mRNA molecules using antisense approaches, based on sequence
specificity of double-stranded nucleic acid interactions should, in theory, allow for design of …

Antisense technology is now beginning to deliver on its promise to treat diseases by
targeting RNA. Nine single-stranded antisense oligonucleotide (ASO) drugs representing …

Recently, there is a hopefully tremendous interest in antisense therapeutics for clinical
purposes. Single‐stranded synthetic antisense oligonucleotides (As‐ODNs) with monomers …

Antisense oligonucleotides (ASOs) are an important tool for the treatment of many genetic
disorders. However, similar to other gene drugs, vectors are often required to protect them …